ASCO® Annual Meeting 2025
Join Tempus at the 2025 ASCO® Annual Meeting as we showcase groundbreaking clinical research and unveil our latest cutting-edge, AI-powered technology and new product offerings—all designed to drive more informed, personalized care across the cancer continuum.
Tempus Evening Reception
Thank you for your interest in our event. The event has concluded, and we are no longer accepting RSVPs. To learn more about Tempus or continue the conversation, please contact us. We will connect you with the right team member.
Experience live demos of our newest technologies for providers, biopharma, and research partners
Stop by our booth to discover how we are leveraging AI-enabled technologies to advance precision oncology.
-
Tempus Hub:
Streamline ordering and get quick access to patient information through our secure online platform. Place orders tailored to your patient’s diagnosis with one-click, view comprehensive smart reports, and review patient medical history—all in one place. -
Tempus One:
Get real-time answers and uncover patient insights with our generative AI assistant built for healthcare providers and researchers. Just ask a question to access data-driven responses instantly. -
Tempus Lens:
Quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets. Explore unstructured clinical data and extract nuanced insights. With Lens, the power of Tempus data is at your fingertips. -
Tempus Next:
Identify patients who may have deviated from care pathways and help providers close gaps in care, accelerating adoption of precision medicine. -
Tempus Link:
Identify prospective clinical trial patients and streamline trial workflows to accelerate clinical trial enrollment with one of the largest, data-integrated oncology trial networks in the nation.
Don't miss the opportunity to see how Tempus is offering one platform for precision oncology by harnessing AI to drive innovation, improve inefficiencies and streamline workflows.
Powering Today’s Insights for a Smarter Tomorrow: Intelligent Diagnostics and AI Solutions Across the Cancer Continuum
At Tempus, AI is infused into everything we do to optimize insights, efficiencies, and tailor patient care. Discover how we’re redefining precision oncology at scale—where our tests fuel smarter decisions and data advances care. Learn how AI, real world data and diagnostics drive innovation.
*Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.
Kate Sasser, PhD, Chief Scientific Officer (Tempus); Ezra Cohen, MD, FASCO, Chief Medical Officer of Oncology (Tempus); Halla Nimeiri, MD, Chief Development Officer (Tempus)
Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment
Poster Board: 213; Abstract: 3544
Veronica Conca, GONO (University of Pisa) & Victoria Chiou (Tempus)
Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants
Poster Board: 241; Abstract: 3572
Faran Polani (Inova Schar Cancer Institute)
Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients
Poster Board: 499; Abstract: 11160
Katie Mo (Tempus), Kunal Nagpal (Tempus)
GEMINI-NSCLC Study - Integrated Longitudinal Multi-Omic Biomarker Profiling Study of Non-Small Cell Lung Cancer (NSCLC) Patients
Poster Board: 234B; Abstract: TPS8114
Douglas C. Palmer (AstraZeneca), Virginia Rhodes (Tempus)
ImmunoDriver-1: Driver alterations (dAlts) and their Immunological Implications in Early and Metastatic Non-Small Cell Lung Cancer (NSCLC)
Poster Board: 18; Abstract: 8060
Jason M. Lee (UCLA)
Lipid Metabolic Gene Expression is Associated with Decreased Overall Survival and Immunogenicity in KRAS-STK11 NSCLC
Poster Board: 14; Abstract: 8534
Joshua Pothen (University of Illinois at Chicago)
Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval
Poster Board: 148; Abstract: 6532
Bobby Heuther (Tempus)
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: a comprehensive multi-center study
Poster Board: 20; Abstract: 1041
Samer Alkassis (UCLA Health Jonsson Comprehensive Cancer Center)
A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors
Poster Board: 20; Abstract: 2558
John Guittar (Tempus)
ORAL PRESENTATION: A Technology-Enabled Clinical Trial Matching Program’s Impact on Patient Screening and Trial Enrollment in 2024
Abstract: 1506
Ajeet Garja (Hematology-Oncology Associates Of CNY)
Schedule a meeting with us
We'll be in touch shortly.